Table 4.

Multivariable Analysis of Time to Castration Resistance.

Characteristics	aHR (95% CI)	P-value
HRR alteration present Yes (n = 37) vs. No (n = 114)	1.68 (1.06-2.65)	.027*
Age < = 65 (n=68) vs. > 65 yo (n = 83)	1.10 (0.73-1.66)	.65
PSA at mHSPC diagnosis	1.00 (0.99-1.01)	.12
Volume of Disease High (n = 72) vs. Low (n = 75)	1.67 (1.02-2.74)	.044*
Visceral metastases Present (n = 27) vs. Not (n = 124)	0.89 (0.48-1.63)	.70
De novo metastatic (N = 93) vs. Not (n = 58)	1.01 (0.65-1.57)	.97
mHSPC therapy
ADT Alone [n = 69]	Reference	-
ADT + ARSI [n = 41]	0.42 (0.23-0.77)	.005*
ADT + Docetaxel [n = 41]	0.70 (0.40-1.23)	.21

^*P < .05 considered statistically significant.Abbreviations: aHR (Adjusted Hazard Ratio)